Current HIV/AIDS Reports

, Volume 11, Issue 4, pp 447–458 | Cite as

Contraceptive Methods and Risk of HIV Acquisition or Female-to-Male Transmission

  • Lisa B. Haddad
  • Chelsea B. Polis
  • Anandi N. Sheth
  • Jennifer Brown
  • Athena P. Kourtis
  • Caroline King
  • Rana Chakraborty
  • Igho Ofotokun
Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Abstract

Effective family planning with modern contraception is an important intervention to prevent unintended pregnancies which also provides personal, familial, and societal benefits. Contraception is also the most cost-effective strategy to reduce the burden of mother-to-child HIV transmission for women living with HIV who wish to prevent pregnancy. There are concerns, however, that certain contraceptive methods, in particular the injectable contraceptive depot medroxyprogesterone acetate (DMPA), may increase a woman’s risk of acquiring HIV or transmitting it to uninfected males. These concerns, if confirmed, could potentially have large public health implications. This paper briefly reviews the literature on use of contraception among women living with HIV or at high risk of HIV infection. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommendations place no restrictions on the use of hormonal contraceptive methods by women with or at high risk of HIV infection, although a clarification recommends that, given uncertainty in the current literature, women at high risk of HIV who choose progestogen-only injectable contraceptives should be informed that it may or may not increase their risk of HIV acquisition and should also be informed about and have access to HIV preventive measures, including male or female condoms.

Keywords

HIV AIDS Contraception Hormonal contraception Transmission 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Lisa B. Haddad, Chelsea B. Polis, Anandi N. Sheth, Athena P. Kourtis, and Caroline King declare that they have no conflict of interest.

Jennifer Brown has received a grant from the NIH.

Rana Chakraborty has received a grant from the CDC and Gilead.

Igho Ofotokun has received a grant from Bristol-Myers Squibb.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the United States Agency for International Development.

References

Papers of particular interest, published recently, have been highlighted as: • Of major importance

  1. 1.
    Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plan. 2010;41(4):241–50.Google Scholar
  2. 2.
    Mavranezouli I. Health economics of contraception. Best Pract Res Clin Obstet Gynaecol. 2009;23(2):187–98.PubMedGoogle Scholar
  3. 3.
    Singh S, Darroch JE. Adding it up: costs and benefits of contraceptive services: estimates for 2012. 2012.Google Scholar
  4. 4.
    Wilcher R et al. From effectiveness to impact: contraception as an HIV prevention intervention. Sex Transm Infect. 2008;84 Suppl 2:ii54–60.PubMedGoogle Scholar
  5. 5.
    World Health Organization. Hormonal contraception and HIV technical statement. Geneva: World Health Organization; 2012.Google Scholar
  6. 6.
    The Inter-agency Task Team for Prevention and Treatment of HIV Infection in Pregnant Women, M, and their Children. Preventing HIV and unintended pregnancies: strategic framework 2011–2015. 2012. http://www.unfpa.org/webdav/site/global/shared/documents/publications/2012/PreventingHIV_UnintendedPregnancies_SF2011_2015.pdf.
  7. 7.
    Johnston B et al. Meeting the family planning needs of women living with HIV in US government global health programs. AIDS. 2013;27 Suppl 1:S121–5.PubMedGoogle Scholar
  8. 8.•
    World Health Organization. Dissemination and evaluation of the 2014 guidance statement on hormonal contraceptive methods for women at high risk and living with HIV. Geneva: WHO; 2014. This report reviews the most recent evidence and summarizes the current guidelines on the topic from the World Health Organization.Google Scholar
  9. 9.
    Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. AIDS. 2013;27(5):787–94.PubMedGoogle Scholar
  10. 10.
    Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis. 2013;13(9):797–808.PubMedGoogle Scholar
  11. 11.•
    Polis CB, Phillips SJ, Curtis KM. Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. AIDS. 2013;27(4):493–505. This is a systematic review of the literature through 2012 evaluating the epidemiological evidence on use of various hormonal contraceptive methods and female-to-male HIV transmission.PubMedGoogle Scholar
  12. 12.•
    Polis CB et al. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Contraception. 2014;90(4):360–90. This is a systematic review of the epidemiological evidence on use of evaluating use of various hormonal contraceptive methods and HIV acquisition in women.PubMedGoogle Scholar
  13. 13.
    Hatcher R et al. Contraceptive technology. 20th ed. New York: Ardent Media; 2011.Google Scholar
  14. 14.
    Adair T. DHS working papers—men’s condom use in higher-risk sex: trends and determinants in five Sub-Saharan countries. Maryland: USAID; 2008.Google Scholar
  15. 15.
    Padian NS et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370(9583):251–61.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Wilkinson D et al. Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. Cochrane Database Syst Rev. 2002;4:CD003939.PubMedGoogle Scholar
  17. 17.
    Wilkinson D et al. Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. Cochrane Database Syst Rev. 2002;4:CD003936.PubMedGoogle Scholar
  18. 18.
    Frank-Herrmann P et al. The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple’s sexual behaviour during the fertile time: a prospective longitudinal study. Hum Reprod. 2007;22(5):1310–9.PubMedGoogle Scholar
  19. 19.
    Trussell J. Contraceptive efficacy. Arch Dermatol. 1995;131(9):1064–8.PubMedGoogle Scholar
  20. 20.
  21. 21.•
    Heffron R et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12(1):19–26. This frequently cited paper is a secondary analysis from a large cohort study. The analysis suggested an increased risk of HIV acquisition and transmission to men associated with use of injectable contraception, and increased global attention to this potential risk.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Lavreys L et al. Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS. 2004;18(4):695–7.PubMedGoogle Scholar
  23. 23.
    Marx PA et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med. 1996;2(10):1084–9.PubMedGoogle Scholar
  24. 24.
    Kapiga SH et al. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS. 1998;12(1):75–84.PubMedGoogle Scholar
  25. 25.
    Myer L et al. Prospective study of hormonal contraception and women’s risk of HIV infection in South Africa. Int J Epidemiol. 2007;36(1):166–74.PubMedGoogle Scholar
  26. 26.
    Taneepanichskul S, Phuapradit W, Chaturachinda K. Association of contraceptives and HIV-1 infection in Thai female commercial sex workers. Aust N Z J Obstet Gynaecol. 1997;37(1):86–8.PubMedGoogle Scholar
  27. 27.
    Kiddugavu M et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS. 2003;17(2):233–40.PubMedGoogle Scholar
  28. 28.
    Morrison CS et al. Hormonal contraception and the risk of HIV acquisition. AIDS. 2007;21(1):85–95.PubMedGoogle Scholar
  29. 29.
    Morrison CS et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS. 2012;26(4):497–504.PubMedGoogle Scholar
  30. 30.
    Bulterys M et al. Hormonal contraception and incident HIV-1 infection: new insight and continuing challenges. AIDS. 2007;21(1):97–9.PubMedGoogle Scholar
  31. 31.
    Morrison CS. Commentary: hormonal contraception and HIV acquisition—current evidence and ongoing research needs. Int J Epidemiol. 2007;36(1):175–7.PubMedGoogle Scholar
  32. 32.
    Polis CB et al. Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches. AIDS. 2013;27 Suppl 1:S35–43.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Wand H, Ramjee G. The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS. 2012;26(3):375–80.PubMedGoogle Scholar
  34. 34.
    Baeten JM et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS. 2007;21(13):1771–7.PubMedGoogle Scholar
  35. 35.
    Morrison CS et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS. 2010;24(11):1778–81.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Heffron R et al. Use of hormonal contraceptives and risk of HIV-1 transmission—authors’ reply. Lancet Infect Dis. 2012;12(8):510–1.Google Scholar
  37. 37.
    Reid SE et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr. 2010;53(5):606–13.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Kleinschmidt I et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception. 2007;75(6):461–7.PubMedGoogle Scholar
  39. 39.
    McCoy SI et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS. 2013;27(6):1001–9.PubMedGoogle Scholar
  40. 40.
    Morrison C, et al. Hormonal contraception and HIV infection: results from a large individual participant data meta-analysis. Presented at AIDS 2014, July 20–25, 2014: Melbourne, Australia.Google Scholar
  41. 41.
    Wall K, et al. Weighing 17 years of evidence: does hormonal contraception increase HIV acquisition risk among Zambian women in discordant couples? Presented at AIDS 2014, July 20–25, 2014: Melbourne, Australia.Google Scholar
  42. 42.
    Lutalo T et al. Effects of hormonal contraceptive use on HIV acquisition and transmission among HIV-discordant couples. AIDS. 2013;27 Suppl 1:S27–34.PubMedGoogle Scholar
  43. 43.•
    Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev. 2010;31(1):79–97. This paper reviews the potential biologic mechanisms from hormones that could affect HIV risk.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Sonnex C. Influence of ovarian hormones on urogenital infection. Sex Transm Infect. 1998;74(1):11–9.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Trunova N et al. Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology. 2006;352(1):169–77.PubMedGoogle Scholar
  46. 46.
    Smith SM, Baskin GB, Marx PA. Estrogen protects against vaginal transmission of simian immunodeficiency virus. J Infect Dis. 2000;182(3):708–15.PubMedGoogle Scholar
  47. 47.
    Smith SM et al. Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect. AIDS. 2004;18(12):1637–43.PubMedGoogle Scholar
  48. 48.
    Gorodeski GI. Estrogen modulation of epithelial permeability in cervical-vaginal cells of premenopausal and postmenopausal women. Menopause. 2007;14(6):1012–9.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Gorodeski GI. Estrogen decrease in tight junctional resistance involves matrix-metalloproteinase-7-mediated remodeling of occludin. Endocrinology. 2007;148(1):218–31.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Goode D et al. Sex hormones selectively impact the endocervical mucosal microenvironment: implications for HIV transmission. PLoS ONE. 2014;9(5):e97767.PubMedCentralPubMedGoogle Scholar
  51. 51.
    Bahamondes MV, et al. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate. Contraception, 2014.Google Scholar
  52. 52.
    Mitchell CM, et al. Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells. J Infect Dis, 2014.Google Scholar
  53. 53.
    Kutteh WH, Moldoveanu Z, Mestecky J. Mucosal immunity in the female reproductive tract: correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res Hum Retrovir. 1998;14 Suppl 1:S51–5.PubMedGoogle Scholar
  54. 54.
    White HD et al. Mucosal immunity in the human female reproductive tract: cytotoxic T lymphocyte function in the cervix and vagina of premenopausal and postmenopausal women. Am J Reprod Immunol. 1997;37(1):30–8.PubMedGoogle Scholar
  55. 55.
    Lu FX et al. Effects of ovarian steroids on immunoglobulin-secreting cell function in healthy women. Clin Diagn Lab Immunol. 2003;10(5):944–9.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Cherpes TL et al. Medroxyprogesterone acetate inhibits CD8+ T cell viral-specific effector function and induces herpes simplex virus type 1 reactivation. J Immunol. 2008;181(2):969–75.PubMedCentralPubMedGoogle Scholar
  57. 57.
    Laskarin G et al. Progesterone directly and indirectly affects perforin expression in cytolytic cells. Am J Reprod Immunol. 1999;42(5):312–20.PubMedGoogle Scholar
  58. 58.
    Scanlan JM et al. Natural killer cell activity is reduced in association with oral contraceptive use. Psychoneuroendocrinology. 1995;20(3):281–7.PubMedGoogle Scholar
  59. 59.
    Yovel G, Shakhar K, Ben-Eliyahu S. The effects of sex, menstrual cycle, and oral contraceptives on the number and activity of natural killer cells. Gynecol Oncol. 2001;81(2):254–62.PubMedGoogle Scholar
  60. 60.
    Chandra N et al. Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retrovir. 2013;29(3):592–601.PubMedCentralPubMedGoogle Scholar
  61. 61.
    King AE, Critchley HO, Kelly RW. Innate immune defences in the human endometrium. Reprod Biol Endocrinol. 2003;1:116.PubMedCentralPubMedGoogle Scholar
  62. 62.
    Ochiel DO et al. Innate immunity in the female reproductive tract: role of sex hormones in regulating uterine epithelial cell protection against pathogens. Curr Womens Health Rev. 2008;4(2):102–17.PubMedCentralPubMedGoogle Scholar
  63. 63.
    Fahey JV, Wira CR. Effect of menstrual status on antibacterial activity and secretory leukocyte protease inhibitor production by human uterine epithelial cells in culture. J Infect Dis. 2002;185(11):1606–13.PubMedGoogle Scholar
  64. 64.
    Keller MJ et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS. 2007;21(4):467–76.PubMedGoogle Scholar
  65. 65.
    Li A et al. Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. Fertil Steril. 2008;90(3):872–5.PubMedGoogle Scholar
  66. 66.
    Mugo NR et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS. 2011;25(15):1887–95.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Miller L et al. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol. 2000;96(3):431–9.PubMedGoogle Scholar
  68. 68.
    Hayes R et al. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS. 2010;24 Suppl 4:S15–26.PubMedGoogle Scholar
  69. 69.
    Low N et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med. 2011;8(2):e1000416.PubMedCentralPubMedGoogle Scholar
  70. 70.
    McClelland RS et al. Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis. 2005;191(3):333–8.PubMedGoogle Scholar
  71. 71.
    Morrison CS et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis. 2004;31(9):561–7.PubMedGoogle Scholar
  72. 72.
    Baeten JM et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3(77):77ra29.PubMedCentralPubMedGoogle Scholar
  73. 73.
    Clemetson DB et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA. 1993;269(22):2860–4.PubMedGoogle Scholar
  74. 74.
    Tanton C et al. Correlates of HIV-1 genital shedding in Tanzanian women. PLoS ONE. 2011;6(3):e17480.PubMedCentralPubMedGoogle Scholar
  75. 75.
    Kreiss J et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis. 1994;170(6):1597–601.PubMedGoogle Scholar
  76. 76.
    Morrison CS et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS. 2010;24(4):573–82.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Henin Y et al. Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Immune Defic Syndr. 1993;6(1):72–5.PubMedGoogle Scholar
  78. 78.
    Gardella B et al. HIV shedding in cervico-vaginal secretions in pregnant women. Curr HIV Res. 2011;9(5):313–20.PubMedGoogle Scholar
  79. 79.
    Ghanem KG et al. Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis. 2005;191(3):358–66.PubMedGoogle Scholar
  80. 80.
    Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis. 2008;35(11):946–59.PubMedGoogle Scholar
  81. 81.
    Rotchford K, Strum AW, Wilkinson D. Effect of coinfection with STDs and of STD treatment on HIV shedding in genital-tract secretions: systematic review and data synthesis. Sex Transm Dis. 2000;27(5):243–8.PubMedGoogle Scholar
  82. 82.
    Ward H, Ronn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5(4):305–10.PubMedCentralPubMedGoogle Scholar
  83. 83.
    Radzio J et al. Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques. AIDS. 2014;28(10):1431–9.PubMedGoogle Scholar
  84. 84.
    Africander D et al. Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception. 2011;84(4):423–35.PubMedGoogle Scholar
  85. 85.
    Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011;76(7):636–52.PubMedGoogle Scholar
  86. 86.
    Hapgood JP et al. Differential glucocorticoid receptor-mediated effects on immunomodulatory gene expression by progestin contraceptives: implications for HIV-1 pathogenesis. Am J Reprod Immunol. 2014;71(6):505–12.PubMedGoogle Scholar
  87. 87.
    Govender Y et al. The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor. PLoS ONE. 2014;9(5):e96497.PubMedCentralPubMedGoogle Scholar
  88. 88.
    Richardson BA et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS. 1999;13(15):2091–7.PubMedGoogle Scholar
  89. 89.
    European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ. 1992;304:809–13.Google Scholar
  90. 90.
    Achilles SL et al. Changes in genital tract immune cell populations after initiation of intrauterine contraception. Am J Obstet Gynecol. 2014. doi: 10.1016/j.ajog.2014.05.016.PubMedGoogle Scholar
  91. 91.
    Van Damme L et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971–7.PubMedGoogle Scholar
  92. 92.
    Centers for Disease Control and Prevention (CDC). U.S. medical eligibility criteria for contraceptive use. Morbidity and Mortality Weekly Report (MMWR), 2010.Google Scholar
  93. 93.
    Anderson JE, Santelli J, Gilbert BC. Adolescent dual use of condoms and hormonal contraception: trends and correlates 1991-2001. Sex Transm Dis. 2003;30(9):719–22.PubMedGoogle Scholar
  94. 94.
    Greydanus DE, Patel DR, Rimsza ME. Contraception in the adolescent: an update. Pediatrics. 2001;107(3):562–73.PubMedGoogle Scholar
  95. 95.
    Anderson JE, Santelli J, Mugalla C. Changes in HIV-related preventive behavior in the US population: data from national surveys, 1987-2002. J Acquir Immune Defic Syndr. 2003;34(2):195–202. 1999.PubMedGoogle Scholar
  96. 96.
    Crosby RA et al. Correlates of using dual methods for sexually transmitted diseases and pregnancy prevention among high-risk African-American female teens. J Adolesc Health. 2001;28(5):410–4.PubMedGoogle Scholar
  97. 97.
    Sales JM et al. Differences between dual-method and non-dual-method protection use in a sample of young African American women residing in the Southeastern United States. Arch Pediatr Adolesc Med. 2010;164(12):1125–31.PubMedGoogle Scholar
  98. 98.
    MacPhail C et al. Predictors of dual method use for pregnancy and HIV prevention among adolescent South African women. Contraception. 2007;75(5):383–9.PubMedGoogle Scholar
  99. 99.
    Massad LS et al. Contraceptive use among U.S. women with HIV. J Women’s Health. 2007;16(5):657–66. 15409996.Google Scholar
  100. 100.
    Higgins JA et al. Dual method use at last sexual encounter: a nationally representative, episode-level analysis of US men and women. Contraception. 2014;90:399–406.PubMedGoogle Scholar
  101. 101.
    Santelli JS et al. The use of condoms with other contraceptive methods among young men and women. Fam Plan Perspect. 1997;29(6):261–7.Google Scholar
  102. 102.
    Santelli JS et al. Combined use of condoms with other contraceptive methods among inner-city Baltimore women. Fam Plan Perspect. 1995;27(2):74–8.Google Scholar
  103. 103.
    Brown JL et al. Multiple method contraception use among African American adolescents in four US cities. Infect Dis Obstet Gynecol. 2011;2011:765917.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Credé S et al. Factors impacting knowledge and use of long acting and permanent contraceptive methods by postpartum HIV positive and negative women in Cape Town, South Africa: a cross-sectional study. BMC Public Health. 2012;12:197.PubMedCentralPubMedGoogle Scholar
  105. 105.
    Dhont N et al. Improved access increases postpartum uptake of contraceptive implants among HIV-positive women in Rwanda. Eur J Contracept Reprod Health Care. 2009;14(6):420–5.PubMedGoogle Scholar
  106. 106.
    Heffron R et al. A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships. Sex Transm Dis. 2010;37(10):621–8.PubMedGoogle Scholar
  107. 107.
    Kikuchi K et al. High rate of unintended pregnancies after knowing of HIV infection among HIV positive women under antiretroviral treatment in Kigali, Rwanda. Biosci Trends. 2011;5(6):255–63.PubMedGoogle Scholar
  108. 108.
    Laher F et al. A qualitative assessment of decisions affecting contraceptive utilization and fertility intentions among HIV-positive women in Soweto, South Africa. AIDS Behav. 2009;13 Suppl 1:47–54.PubMedGoogle Scholar
  109. 109.
    Nduna M, Farlane L. Women living with HIV in South Africa and their concerns about fertility. AIDS Behav. 2009;13 Suppl 1:62–5.PubMedGoogle Scholar
  110. 110.
    Polis CB et al. Trends and correlates of hormonal contraceptive use among HIV-infected women in Rakai, Uganda, 1994-2006. Contraception. 2011;83(6):549–55.PubMedGoogle Scholar
  111. 111.
    Ezeanolue EE et al. Contraception choices in a cohort of HIV+ women in the era of highly active antiretroviral therapy. Contraception. 2011;84(1):94–7.PubMedGoogle Scholar
  112. 112.
    Carrieri MP et al. Oral contraception and unprotected sex with occasional partners of women HIV-infected through injection drug use. AIDS Care. 2006;18(7):795–800.PubMedGoogle Scholar
  113. 113.
    Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect. 2011;87(3):183–90.PubMedGoogle Scholar
  114. 114.
    Taiwo B. Understanding transmitted HIV resistance through the experience in the USA. Int J Infect Dis. 2009;13(5):552–9.PubMedGoogle Scholar
  115. 115.
    Campbell MS et al. HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk? PLoS ONE. 2009;4(5):e5690.PubMedCentralPubMedGoogle Scholar
  116. 116.
    Brenner B et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (London, England). 2004;18(12):1653–60.Google Scholar
  117. 117.
    Bouhlal H et al. Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol. 2002;169(6):3301–6.PubMedGoogle Scholar
  118. 118.
    Gutsche S et al. Seminal plasma induces mRNA expression of IL-1beta, IL-6 and LIF in endometrial epithelial cells in vitro. Mol Hum Reprod. 2003;9(12):785–91.PubMedGoogle Scholar
  119. 119.
    Sharkey DJ et al. Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod. 2007;13(7):491–501.PubMedGoogle Scholar
  120. 120.
    Sharkey DJ et al. Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol. 2012;188(5):2445–54.PubMedGoogle Scholar
  121. 121.
    Berlier W et al. Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: involvement in the sexual transmission of HIV. Hum Reprod. 2006;21(5):1135–42.PubMedGoogle Scholar
  122. 122.
    White HD et al. CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. J Immunol. 1997;158(6):3017–27.PubMedGoogle Scholar
  123. 123.
    Plummer FA. Heterosexual transmission of human immunodeficiency virus type 1 (HIV): interactions of conventional sexually transmitted diseases, hormonal contraception and HIV-1. AIDS Res Hum Retrovir. 1998;14 Suppl 1:S5–10.PubMedGoogle Scholar
  124. 124.
    Cu-Uvin S et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14(4):415–21.PubMedGoogle Scholar
  125. 125.
    Kovacs A et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358(9293):1593–601.PubMedGoogle Scholar
  126. 126.
    Cohen MS et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCentralPubMedGoogle Scholar
  127. 127.
    Flynn PM et al. Long-term observation of adolescents initiating HAART therapy: three-year follow-Up. AIDS Res Hum Retrovir. 2007;23(10):1208–14.PubMedGoogle Scholar
  128. 128.
    Murphy DA et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157(3):249–55.PubMedGoogle Scholar
  129. 129.
    Murphy DA et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13(1):27–40.PubMedGoogle Scholar
  130. 130.
    Roccio M et al. Low-dose combined oral contraceptive and cervicovaginal shedding of human immunodeficiency virus. Contraception. 2011;83(6):564–70.PubMedGoogle Scholar
  131. 131.
    Debiaggi M et al. Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy. Eur J Clin Microbiol Infect Dis. 2001;20(2):91–6.PubMedGoogle Scholar
  132. 132.
    Rasheed S. Infectivity and dynamics of HIV type 1 replication in the blood and reproductive tract of HIV type 1-infected women. AIDS Res Hum Retrovir. 1998;14 Suppl 1:S105–18.PubMedGoogle Scholar
  133. 133.
    Donnell D et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8.PubMedCentralPubMedGoogle Scholar
  134. 134.
    Del Romero J et al. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ. 2010;340:c2205.PubMedCentralPubMedGoogle Scholar
  135. 135.
    Neely MN et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44(1):38–42.PubMedCentralPubMedGoogle Scholar
  136. 136.
    Fiore JR et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS. 2003;17(15):2169–76.PubMedGoogle Scholar
  137. 137.
    Andreoletti L et al. Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital-tract secretions of clinically asymptomatic, treatment-naive African women. J Infect Dis. 2003;188(4):549–54.PubMedGoogle Scholar
  138. 138.
    Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis. 2010;51(6):725–31.PubMedCentralPubMedGoogle Scholar
  139. 139.
    Anton P, Herold BC. HIV transmission: time for translational studies to bridge the gap. Sci Transl Med. 2011;3(77):77ps11.PubMedCentralPubMedGoogle Scholar
  140. 140.
    Day S et al. A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;66(4):452–6.PubMedGoogle Scholar
  141. 141.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2013 updated 7/31/12; cited 2013 November 14. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
  142. 142.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Editor.Google Scholar
  143. 143.
    Centers for Disease Control and Prevention (CDC). Update to CDC’s U.S. medical eligibility criteria for contraceptive use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR. 2012;61(24):449–52.Google Scholar
  144. 144.
    Rodriguez MI, Reeves MF, Caughey AB. Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: a decision analysis. BJOG. 2012;119(9):1067–73.PubMedGoogle Scholar
  145. 145.
    Butler AR et al. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS. 2013;27(1):105–13.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Lisa B. Haddad
    • 1
  • Chelsea B. Polis
    • 2
  • Anandi N. Sheth
    • 3
  • Jennifer Brown
    • 4
  • Athena P. Kourtis
    • 5
  • Caroline King
    • 5
  • Rana Chakraborty
    • 6
  • Igho Ofotokun
    • 3
  1. 1.Department of Gynecology and ObstetricsEmory University School of MedicineAtlantaUSA
  2. 2.Office of Population and Reproductive HealthUnited States Agency for International Development (USAID)WashingtonUSA
  3. 3.Department of Medicine, Division of Infectious Diseases and Grady Healthcare SystemEmory University School of MedicineAtlantaUSA
  4. 4.Department of Psychological SciencesTexas Tech UniversityLubbockUSA
  5. 5.Division of Reproductive Health, Centers for Disease Control and PreventionNational Center for Chronic Disease Prevention and Health PromotionAtlantaUSA
  6. 6.Department of Pediatrics, Division of Infectious DiseasesEmory University School of MedicineAtlantaUSA

Personalised recommendations